Vivos Therapeutics (NASDAQ:VVOS) Price Target Cut to $3.00 by Analysts at Ascendiant Capital Markets

Vivos Therapeutics (NASDAQ:VVOS) had its target price reduced by Ascendiant Capital Markets from $5.50 to $3.00 in a report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also issued reports on VVOS. HC Wainwright lowered their price target on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research note on Friday, April 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Monday. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $2.58.

Vivos Therapeutics Price Performance

Shares of VVOS stock opened at $1.03 on Wednesday. The company has a current ratio of 0.24, a quick ratio of 0.24 and a debt-to-equity ratio of 3.31. Vivos Therapeutics has a 1 year low of $0.96 and a 1 year high of $7.95. The firm’s fifty day moving average price is $1.31 and its two-hundred day moving average price is $1.93. The firm has a market capitalization of $13.89 million, a P/E ratio of -0.50 and a beta of 6.93.

Vivos Therapeutics (NASDAQ:VVOS) last issued its quarterly earnings results on Wednesday, April 15th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.08). Vivos Therapeutics had a negative net margin of 121.37% and a negative return on equity of 849.22%. The business had revenue of $3.82 million during the quarter, compared to analyst estimates of $7.10 million. During the same quarter in the previous year, the firm posted ($2.22) earnings per share. On average, equities analysts predict that Vivos Therapeutics will post -1.45 EPS for the current fiscal year.

Insider Activity at Vivos Therapeutics

In related news, major shareholder Michael C. Skaff bought 1,353,625 shares of Vivos Therapeutics stock in a transaction that occurred on Tuesday, March 31st. The stock was acquired at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the acquisition, the insider owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 2.10% of the company’s stock.

Institutional Trading of Vivos Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Acorn Wealth Advisors LLC bought a new stake in Vivos Therapeutics in the 4th quarter valued at about $30,000. XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics during the 2nd quarter worth approximately $65,000. Connective Capital Management LLC acquired a new position in shares of Vivos Therapeutics during the 3rd quarter worth approximately $620,000. DRW Securities LLC grew its position in shares of Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after purchasing an additional 74,441 shares in the last quarter. Finally, B. Riley Wealth Advisors Inc. acquired a new position in shares of Vivos Therapeutics during the 2nd quarter worth approximately $220,000. Institutional investors own 26.35% of the company’s stock.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.